Phase 2 study of Renzapride in patients with diabetic gastroparesis

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Aug 2017 According to an EndoLogic media release, company anticipate submitting the IND in the fourth quarter of 2017, with dosing of the first patient expected in the second quarter of 2018.
09 Aug 2017 According to an EndoLogic media release, if successful, this study will be considered as one of two pivotal trials essential to submit an NDA.
03 May 2017 According to an EndoLogic media release, the FDA has scheduled a pre-IND meeting with EndoLogic to discuss the requirements for this proposed phase II study. The meeting will be on July 25, 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com